Ascendis Pharma A/S $ASND Stock Bought by Diversified Trust Co

Diversified Trust Co boosted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 17.7% in the third quarter, HoldingsChannel reports. The fund owned 30,581 shares of the biotechnology company’s stock after acquiring an additional 4,590 shares during the period. Diversified Trust Co’s holdings in Ascendis Pharma A/S were worth $6,967,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Allworth Financial LP grew its holdings in Ascendis Pharma A/S by 103.4% in the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 122 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 69 shares in the last quarter. Fifth Third Bancorp lifted its holdings in shares of Ascendis Pharma A/S by 48.4% during the third quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 91 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 94.9% during the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 148 shares during the last quarter. Finally, IFP Advisors Inc lifted its holdings in shares of Ascendis Pharma A/S by 3,491.7% during the second quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 419 shares during the last quarter.

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president owned 3,000 shares of the company’s stock, valued at approximately $810,570. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 40.00% of the stock is owned by company insiders.

Trending Headlines about Ascendis Pharma A/S

Here are a few of the latest headlines about ASND:

• Positive Sentiment: Q3 results and commercial growth were strong. Ascendis reported revenue of $418.7 million, above analyst expectations, while product revenue reached €366 million, up 89% year over year. YORVIPATH accounted for €291 million of product sales. The company also reported a quarterly profit, marking a shift toward commercial-scale profitability. Ascendis Pharma Q3 2026 results
• Positive Sentiment: Analyst updates lean bullish. TD Cowen raised its target to $352 and UBS lifted its target to $315, both maintaining buy ratings. Cantor Fitzgerald also raised its target to $315 with an overweight rating; RBC reaffirmed outperform at $290. These higher targets indicate continued analyst confidence in the outlook. Read More. · Read More. · Read More. · Read More.
• Neutral Sentiment: Analyst views are not unanimous. Canaccord raised its target to $274 but kept a hold rating, while HC Wainwright cut its target to $335, though it retained a buy rating. Read More. · Read More.

Ascendis Pharma A/S Stock Up 3.1%

Shares of Ascendis Pharma A/S stock opened at $275.39 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99. The stock has a market capitalization of $17.18 billion, a PE ratio of 18.00 and a beta of 0.40. Ascendis Pharma A/S has a 52-week low of $188.08 and a 52-week high of $282.15. The company has a 50-day simple moving average of $242.67 and a two-hundred day simple moving average of $239.83.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 44.80% and a net margin of 73.26%. The firm had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. On average, analysts anticipate that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Bank of America dropped their price target on Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. Barclays reduced their price objective on Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating for the company in a research report on Friday, August 14th. Raymond James Financial reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Friday. Oppenheimer boosted their target price on Ascendis Pharma A/S from $304.00 to $312.00 and gave the stock an “outperform” rating in a report on Tuesday, September 1st. Finally, Wells Fargo & Company boosted their target price on Ascendis Pharma A/S from $326.00 to $330.00 and gave the stock an “overweight” rating in a report on Friday. Nineteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $313.52.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.